CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS

Korábbi kezelés

• Use of PCSK9 inhibitors (e.g., evolocumab, alirocumab) or potent CYP3A4 inhibitors (e.g., itraconazole) within the last 12 months.
• Known intolerance to statins, evolocumab, or other investigational drugs related to the study.

Más betegség

• History of coronary artery bypass grafting (CABG).
• History of valve surgery.
• History of PCI treatment before the index ACS event
• Active autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).
• Uncontrolled heart failure (NYHA class III-IV) or malignant arrhythmias.
• Known allergy or hypersensitivity to iodinated contrast media
• Hyperthyroidism or active thyroid disease
• Life expectancy of less than 1 year (e.g., due to advanced malignancy).

Laborértékek

• Hepatic or renal insufficiency (eGFR <60 mL/min/1.73m² or ALT/AST >3 times the upper limit of normal).

Egyéb

• Complex bifurcation lesions (Medina 1,1,1).
• Pregnancy or breastfeeding (or plans for pregnancy within the next year).
• Participation in another interventional clinical trial within the past 3 months.

• Eligible patients must meet the following criteria:
• Age between 40 and 75 years.
• Diagnosis of ACS, including ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) or unstable angina (UA).
• Successful PCI treatment, with post-procedural TIMI grade 3 flow and residual stenosis <30% and atherosclerotic plaque presence in non-culprit coronary vessels (not attributed to this target event).
• Suboptimal LDL-C control: Patients must have received any statin treatment for at least 4 weeks, with an LDL-C level ≥1.8 mmol/L; or Statin-naive patients must have an LDL-C level ≥3.2 mmol/L.
• Agreement to complete baseline CCTA and laboratory tests within 7 days of enrollment and signed informed consent.
• Commitment to complete 52 weeks of follow-up.